scholarly journals The Drug Discovery and Development Industry in India-Two Decades of Proprietary Small-Molecule R&D

ChemMedChem ◽  
2017 ◽  
Vol 12 (11) ◽  
pp. 786-818 ◽  
Author(s):  
Edmond Differding
Keyword(s):  
Drug Discovery ◽  
Small Molecule ◽  
Drug Discovery And Development

scholarly journals Glossary and tutorial of xenobiotic metabolism terms used during small molecule drug discovery and development (IUPAC Technical Report)

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Paul Erhardt ◽  
Kenneth Bachmann ◽  
Donald Birkett ◽  
Michael Boberg ◽  
Nicholas Bodor ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Small Molecule ◽  
Chemical Structure ◽  
Early Stage ◽  
Xenobiotic Metabolism ◽  
Drug Discovery And Development ◽  
Small Molecule Drug ◽  
Technical Report ◽  
Wide Range ◽  
Draft Version

Abstract This project originated more than 15 years ago with the intent to produce a glossary of drug metabolism terms having definitions especially applicable for use by practicing medicinal chemists. A first-draft version underwent extensive beta-testing that, fortuitously, engaged international audiences in a wide range of disciplines involved in drug discovery and development. It became clear that the inclusion of information to enhance discussions among this mix of participants would be even more valuable. The present version retains a chemical structure theme while expanding tutorial comments that aim to bridge the various perspectives that may arise during interdisciplinary communications about a given term. This glossary is intended to be educational for early stage researchers, as well as useful for investigators at various levels who participate on today’s highly multidisciplinary, collaborative small molecule drug discovery teams.

scholarly journals Drug discovery and development: Biomarkers of neurotoxicity and neurodegeneration

2018 ◽  
Vol 243 (13) ◽  
pp. 1037-1045 ◽  
Author(s):  
Abigail L Walker ◽  
Syed Z Imam ◽  
Ruth A Roberts
Keyword(s):  
Multiple Sclerosis ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Drug Discovery ◽  
Small Molecule ◽  
Treatment Options ◽  
New Drugs ◽  
Drug Discovery And Development ◽  
Non Invasive ◽  
Small Molecule Drug

The discovery and development of new drugs are vital if we are to improve and expand treatment options available to improve outcomes for patients. Overall, therapeutic strategies fall into two broad categories: small molecules and biologics, although more recently there has been a growth in novel platforms such as miRNAs and oligonucleotides. On average, the development of a small molecule drug takes around 12 years and costs around $50m. Despite this huge investment of time and money, attrition remains a major challenge and very few molecules actually make it through to the market. Here, we look at reasons for attrition in the small molecule field with a focus on neurotoxicology and efforts being made to improve success via the development of imaging and fluidic biomarkers. We also look at learnings from other models of CNS damage and degeneration such as Parkinson’s disease, traumatic brain injury, and multiple sclerosis since these may offer the opportunity to improve tools available to nonclinical toxicologists in the early detection of potential neurotoxicity. Reciprocally, learnings from studies of animal neurotoxicity may offer better ways to potentially monitor patients during clinical development of new drugs for neurodegeneration. Impact statement Attrition in drug discovery and development remains a major challenge. Safety/toxicity is the most prevalent reason for failure with cardiovascular and CNS toxicities predominating. Non-invasive biomarkers of neurotoxicity would provide significant advantage by allowing earlier prediction of likely neurotoxicity in preclinical studies as well as facilitating clinical trials of new therapies for neurodegenerative conditions such as Parkinson’s disease (PD) and multiple sclerosis (MS).

scholarly journals Small molecule recognition of disease-relevant RNA structures

2020 ◽  
Vol 49 (19) ◽  
pp. 7167-7199 ◽  
Author(s):  
Samantha M. Meyer ◽  
Christopher C. Williams ◽  
Yoshihiro Akahori ◽  
Toru Tanaka ◽  
Haruo Aikawa ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Small Molecules ◽  
Small Molecule ◽  
Rna Structures ◽  
Drug Discovery And Development ◽  
New Frontier ◽  
Molecule Recognition

Targeting RNAs with small molecules, a new frontier in drug discovery and development.

scholarly journals Pharmaceutical industries: do they prefer treatment to cure?

2005 ◽  
Vol 27 (3) ◽  
pp. 32-34 ◽  
Author(s):  
James Mittra
Keyword(s):  
Drug Discovery ◽  
Small Molecule ◽  
Life Science ◽  
Healthcare Sector ◽  
Pharmaceutical Companies ◽  
Prefer Treatment ◽  
Drug Discovery And Development ◽  
Research Organizations ◽  
Pharmaceutical Industries

Despite the emergence of novel life-science-based approaches to drug discovery and development and the unprecedented growth of new companies and research organizations competing in the healthcare sector, the industry continues to be dominated by the marketing of small-molecule ‘blockbuster’ therapies developed by large multinationals. The hope that ‘genomics’ would shift the focus from the treatment of symptoms associated with disease to the prevention or cure of many debilitating illnesses has yet to translate into reality. The question is whether traditional pharmaceutical companies simply prefer treatment to cure and, if so, where must society look to ensure that the best science is translated into the most innovative, effective and beneficial clinical products.

Sign in / Sign up

Export Citation Format

Share Document